Boditech Med (206640) Fundamentals 2026 — P/E 8.5x, Revenue Analysis | SniperIQ
Boditech Med (206640) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩226.6B, trading at ₩10440.00 on the KOE. This SniperIQ fundamentals page covers Boditech Med's valuation (P/E 8.5x, P/B 0.9x), profitability (net margin 15.7%), revenue (₩162.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Boditech Med's market cap?
Boditech Med (206640) has a market capitalization of approximately ₩226.6B, trading at ₩10440.00 on the KOE. Market cap moves with the live share price.
What is Boditech Med's P/E ratio?
Boditech Med's trailing twelve-month P/E ratio is 8.5x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Boditech Med?
Boditech Med runs a net profit margin of 15.7%, a gross margin of 58.5%, and an operating margin of 16.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Boditech Med generate?
Boditech Med reported revenue of ₩162.0B for fiscal year 2025, with net income of ₩23.7B and earnings per share (EPS) of 1092. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Boditech Med pay a dividend?
Boditech Med offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Boditech Med financially healthy?
Boditech Med carries a debt-to-equity ratio of 0.06x and a current ratio of 5.55x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Boditech Med a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Boditech Med (206640) the key facts are: market cap ₩226.6B, P/E 8.5x, revenue ₩162.0B, 52-week range 9580-15000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Boditech Med's full fundamentals live
Get Boditech Med's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.